The story of the erectile dysfunction drug presents a complex picture for shareholders. While the initial introduction generated substantial profits, the expiration of its patent opened the floodgates to off-brand https://bookmarkingfeed.com/story21532599/sildenafil-and-pharma-a-precarious-bet